Skip to main content
. Author manuscript; available in PMC: 2009 Jun 29.
Published in final edited form as: Vaccine. 2007 Apr 25;25(23):4564–4570. doi: 10.1016/j.vaccine.2007.04.025

Figure 1.

Figure 1

Serum anti-HR-gp100 antibody levels in mice treated topically with 50–100 μg/mouse HR-gp100 produced in yeast, gp100(y), or bacteria, gp100(b), either alone or mixed with nLT. Each treatment was repeated 2 or 3 times in independent experiments; the results of one typical experiment are shown. w – weeks after starting topical treatment. Each group included 3 mice; bars indicate standard error of the means.